Company intelligence / Profile preview

S-Alpha Therapeutics

Seoul, Seoul, South Koreasalphadtx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

S‑Alpha Therapeutics has developed several digital therapeutic products. Its lead program, SAT‑001 for pediatric myopia, is undergoing clinical trials in South Korea and the US. Another program, SAT‑008, focuses on immune system enhancement and is being validated through clinical studies. The company continues to expand its pipeline into new disease areas.

Therapeutic areas: ImmunologyOphthalmology
Modalities: Digital therapeutic (software-based intervention)
Industry: Digital Health Medical Devices

Drug pipeline

6 assets

SAT-001

Clinical trials

Indications: Pediatric myopia

5 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on S-Alpha Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-Alpha Therapeutics.

Explore the full profile